We thank the following national societies and patient organisations who have already endorsed the campaign:

NATIONAL SOCIETIES & PATIENT GROUPS

Visit www.CallAllergyAsthma.eu to see the current list of endorsers from around the world.

Around 1 in 3 Europeans suffer from chronic allergy, the most common chronic disease in Europe.

17 million Europeans live with a food allergy.

Economic benefit

Public health programmes

Funding for research

Prevention and early diagnosis

Root cause analysis of diseases

Personalised medicine

A heart felt thank you for your support!

SHOW YOUR SUPPORT AND ENDORSE TODAY

Endorsing is simple and quick, taking no longer than 5 minutes.

Please visit www.CallAllergyAsthma.eu.

Click on your relevant group and fill out the short form.

Spread the word amongst friends and colleagues using

#CallAllergyAsthma

Together we stand united to create a healthier and happier future for the over 220 million allergy and asthma patients in Europe.

Visit www.CallAllergyAsthma.eu to see the current list of endorsers from around the world.
A POLITICAL CALL TO ACTION IN EUROPE

This is a Call to Action to all European and national stakeholders who are able to improve public policies which address allergy and asthma, supporting patients’ rights. It marks the start of a pan European advocacy campaign initiated by Members of the European Parliament Interest Group on Allergy and Asthma, the European Academy of Allergy and Clinical Immunology (EAACI) and the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA).

WE CALL UPON EU MEMBER STATES TO:
• Provide new or revised national chronic disease policies to include allergy and asthma
• Develop national allergy and asthma programmes built on evidence-based, successful, preventive and tolerance-inducing approaches
• Invest in allergy and asthma prevention and early detection, including awareness campaigns and training programmes for healthcare professionals
• Dedicate national public funding to allergy and asthma research and generate evidence to further reform tailored national policies
• Encourage placing allergy and asthma as a health priority in the agenda of the upcoming EU Council Presidencies

WE CALL UPON THE EUROPEAN COMMISSION TO:
• Promote and support financially, via the EU Health and Cohesion Funds, programmes for healthcare professionals
• Encourage translating research into practice

WE CALL UPON MEMBERS OF THE EUROPEAN PARLIAMENT TO:
• Support this Call to Action and its pan European advocacy campaign
• Raise awareness among EU and Member States citizens
• Encourage the development of coordinated European strategies to foster allergy and asthma programmes
• Promote addressing allergy and asthma in EU and national health and environmental policies

WE CALL UPON CIVIL SOCIETY, PARTICULARLY PATIENTS, HEALTHCARE PROFESSIONALS AND HEALTH ADVOCATES TO:
• Endure and relay the Call to Action
• Engage in joint advocacy of EU to national levels to improve awareness, monitoring, prevention and management of allergy and asthma across Europe
• Engage in dialogue with national governments and EU institutions to share knowledge, expertise and strategic advice to shape policy and successfully act on allergy and asthma in Europe
• Promote personalised allergy and asthma medicine and contribute to shifting E.U. healthcare systems towards more personalized and outcome-based models, that benefit patients, economies and societies

The current burden of allergy and asthma on our society
Allergy and asthma are among the most frequent chronic diseases in the European Union (EU). Over 150 million EU citizens – almost one in three people – suffer from a chronic allergy or asthma.

About 70 million Europeans have asthma

The current burden of allergy and asthma on our society
Allergy and asthma are among the most frequent chronic diseases in the European Union (EU). Over 150 million EU citizens – almost one in three people – suffer from a chronic allergy or asthma.

About 70 million Europeans have asthma

WE CALL UPON THE EUROPEAN COMMISSION TO:
• Place allergy and asthma at the forefront of EU chronic disease strategies
• Encourage coordinated European and national policies on allergy and asthma with a health-friendly approach
• Land coordination support to collect public health indicators and monitor trends on allergy and asthma
• Promote and support financially, via the EU Health Programme, the exchange and dissemination of good practices and programmes among Member States
• Promote and support financially, via Horizon 2020 and future programmes, scientific research to address underlying causes of allergies and develop innovative treatments to cure allergy and asthma
• Encourage greater cooperation and coordination between Member States for harmonised allergy and asthma programmes,

The current burden of allergy and asthma on our society
Allergy and asthma are among the most frequent chronic diseases in the European Union (EU). Over 150 million EU citizens – almost one in three people – suffer from a chronic allergy or asthma. The prevalence of allergy and asthma has increased to alarming proportions in the past decades, many due to increases in pollution, climate change, and lifestyle factors. Addressing these issues requires cross-sectoral and cross-country collaboration among all stakeholders.

As members of the European Parliament, healthcare professionals and patients, we call out to you

Today, there is still no cure for allergy and asthma, and large discrepancies in monitoring, prevention, early diagnosis, treatment and care exist across Europe. Strong and unified European political leadership is urgently needed to successfully curb this dramatic epidemic for the benefit of our patients, economies and society.

WE CALL UPON MEMBER OF THE EUROPEAN PARLIAMENT TO:
• Support this Call to Action and its pan European advocacy campaign
• Raise awareness among EU and Member States citizens
• Encourage the development of coordinated European strategies to foster allergy and asthma programmes
• Address allergy and asthma in future programmes, scientific research to address underlying causes of allergies and develop innovative treatments to cure allergy and asthma

WE CALL UPON CIVIL SOCIETY, PARTICULARLY PATIENTS, HEALTHCARE PROFESSIONALS AND HEALTH ADVOCATES TO:
• Endure and relay the Call to Action
• Engage in joint advocacy of EU to national levels to improve awareness, monitoring, prevention and management of allergy and asthma across Europe
• Engage in dialogue with national governments and EU institutions to share knowledge, expertise and strategic advice to shape policy and successfully act on allergy and asthma in Europe
• Promote personalised allergy and asthma medicine and contribute to shifting E.U. healthcare systems towards more personalized and outcome-based models, that benefit patients, economies and societies

About the initiators of the United Action for Allergy and Asthma campaign

The IP Interest Group on Allergy and Asthma is a common effort by European allergy and asthma patients, health professionals and Members of the European Parliament (MEPs) committed to address what they consider to be the most prevalent chronic diseases in Europe. The prevalence of allergy and asthma has increased to alarming proportions in the past decades, many due to increases in pollution, climate change, and lifestyle factors. Addressing these issues requires cross-sectoral and cross-country collaboration among all stakeholders.

The European Academy of Allergy and Clinical Immunology (EAACI)
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit association including over 60 National Allergy Societies, more than 1,900 academic, research investigators and clinicians from 127 different countries.

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a not-for-profit network of 38 allergy, asthma and chronic obstructive pulmonary disease (COPD) patients’ organisations, representing over 460,000 patients in 24 countries.